PT  - JOURNAL ARTICLE
AU  - Joong-Won Park
AU  - Ji Hoon Kim
AU  - Seok Ki Kim
AU  - Keon Wook Kang
AU  - Kyung Woo Park
AU  - Jun-Il Choi
AU  - Woo Jin Lee
AU  - Chang-Min Kim
AU  - Byung Ho Nam
TI  - A Prospective Evaluation of <sup>18</sup>F-FDG and <sup>11</sup>C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma
AID  - 10.2967/jnumed.108.055087
DP  - 2008 Dec 01
TA  - Journal of Nuclear Medicine
PG  - 1912--1921
VI  - 49
IP  - 12
4099  - http://jnm.snmjournals.org/content/49/12/1912.short
4100  - http://jnm.snmjournals.org/content/49/12/1912.full
SO  - J Nucl Med2008 Dec 01; 49
AB  - Because 18F-FDG PET has insufficient sensitivity for the detection of hepatocellular carcinoma (HCC), 11C-acetate PET has been proposed as another technique for this use. We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC. Methods: One hundred twelve patients (99 with HCC, 13 with cholangiocellular carcinoma) underwent biopsy and 18F-FDG and 11C-acetate PET/CT. Results: The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively. Elevated serum α-fetoprotein levels, an advanced tumor stage, portal vein tumor thrombosis, large tumors, and multiple tumors were significantly associated with positive 18F-FDG PET/CT results. Uptake of 11C-acetate was associated with large and multiple tumors. For 18F-FDG, the sensitivities according to tumor size (1–2, 2–5, and ≥5 cm) were 27.2%, 47.8%, and 92.8%, respectively; for 11C-acetate, these respective values were 31.8%, 78.2%, and 95.2%. 18F-FDG was more sensitive in the detection of poorly differentiated HCC. Overall survival was lower in patients with 18F-FDG PET/CT positive for all indexed lesions than in those with FDG negative or partially positive through the entire follow-up period. In analysis based on biopsied lesions, the sensitivity of 18F-FDG PET/CT was 64.4% for primary HCC and 84.4% for 11C-acetate PET/CT. The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT for 35 metastatic HCCs were 85.7%, 77.0%, and 85.7%, respectively. There was no significant difference in the sensitivity of tracers according to metastatic tumor size, location, or differentiation. Conclusion: The addition of 11C-acetate to 18F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. 18F-FDG, 11C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but 18F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC.